Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia-Reference-Cited by-同舟云学术

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia

Published:2021-01 Issue:1 Volume:7 Page:
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:A&D Transl Res & Clin Interv

Author:

Matthews Dawn C.¹,Ritter Aaron²,Thomas Ronald G.³,Andrews Randolph D.¹,Lukic Ana S.¹,Revta Carolyn⁴,Kinney Jefferson W.⁵,Tousi Babak⁶,Leverenz James B.⁷,Fillit Howard⁸,Zhong Kate⁹,Feldman Howard H.¹⁰,Cummings Jeffrey²¹¹

Affiliation:

1. ADM Diagnostics, Inc. Northbrook Illinois USA

2. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas Nevada USA

3. Department of Family Medicine and Public Health UCSD La Jolla California USA

4. Alzheimer's Disease Cooperative Study University of California San Diego School of Medicine La Jolla California USA

5. Department of Brain Health University of Nevada Las Vegas Las Vegas Nevada USA

6. Neurologic Institute Cleveland Clinic Cleveland Ohio USA

7. Cleveland Clinic Lou Ruvo Center for Brain Health Cleveland Ohio USA

8. Alzheimer's Drug Discovery Foundation New York New York USA

9. CNS Innovations LLC Henderson Nevada USA

10. Department of Neurosciences Alzheimer's Disease Cooperative Study San Diego University of California La Jolla California USA

11. Department of Brain Health Chambers‐Grundy Center for Transformative Neuroscience School of Integrated Health Sciences University of Nevada Las Vegas Nevada USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12106

Reference39 articles.

1. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

2. Dopamine and the regulation of cognition and attention

3. Propargylamine Containing Compounds as Modulators of Proteolytic Cleavage of Amyloid Protein Precursor: Involvement of MAPK and PKC Activation

4. Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline

5. Effects of combined MAO‐B inhibitors and levodopa vs. monotherapy in Parkinson's disease;Krishna R;Front Aging Neurosci,2014

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico screening of multi-target drugs against Alzheimer's Disease: a repurposing approach;2024-08-29

2. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2024-07

3. Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development;CNS Drugs;2024-06-27

4. A Novel MAO-B/SSAO Inhibitor Improves Multiple Aspects of Dystrophic Phenotype in mdx Mice;Antioxidants;2024-05-21

5. Benzodioxane Carboxamide Derivatives As Novel Monoamine Oxidase B Inhibitors with Antineuroinflammatory Activity;ACS Medicinal Chemistry Letters;2024-05-20